Cargando…
Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome
Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome is a rare autoimmune disease due to mutations in the gene encoding for Forkhead box P3 (FOXP3), a transcription factor fundamental for the function of thymus-derived (t) regulatory T (Treg) cells. The dysfunction of Treg...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443799/ https://www.ncbi.nlm.nih.gov/pubmed/25274247 http://dx.doi.org/10.2174/1566523214666141001123828 |
_version_ | 1782373057410629632 |
---|---|
author | Passerini, Laura Santoni de Sio, Francesca R. Porteus, Matthew H. Bacchetta, Rosa |
author_facet | Passerini, Laura Santoni de Sio, Francesca R. Porteus, Matthew H. Bacchetta, Rosa |
author_sort | Passerini, Laura |
collection | PubMed |
description | Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome is a rare autoimmune disease due to mutations in the gene encoding for Forkhead box P3 (FOXP3), a transcription factor fundamental for the function of thymus-derived (t) regulatory T (Treg) cells. The dysfunction of Treg cells results in the development of devastating autoimmune manifestations affecting multiple organs, eventually leading to premature death in infants, if not promptly treated by hematopoietic stem cell transplantation (HSCT). Novel gene therapy strategies can be developed for IPEX syndrome as more definitive cure than allogeneic HSCT. Here we describe the therapeutic approaches, alternative to HSCT, currently under development. We described that effector T cells can be converted in regulatory T cells by LV-mediated FOXP3-gene transfer in differentiated T lymphocytes. Despite FOXP3 mutations mainly affect a highly specific T cell subset, manipulation of stem cells could be required for long-term remission of the disease. Therefore, we believe that a more comprehensive strategy should aim at correcting FOXP3-mutated stem cells. Potentials and hurdles of both strategies will be highlighted here. |
format | Online Article Text |
id | pubmed-4443799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-44437992015-05-28 Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome Passerini, Laura Santoni de Sio, Francesca R. Porteus, Matthew H. Bacchetta, Rosa Curr Gene Ther Article Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome is a rare autoimmune disease due to mutations in the gene encoding for Forkhead box P3 (FOXP3), a transcription factor fundamental for the function of thymus-derived (t) regulatory T (Treg) cells. The dysfunction of Treg cells results in the development of devastating autoimmune manifestations affecting multiple organs, eventually leading to premature death in infants, if not promptly treated by hematopoietic stem cell transplantation (HSCT). Novel gene therapy strategies can be developed for IPEX syndrome as more definitive cure than allogeneic HSCT. Here we describe the therapeutic approaches, alternative to HSCT, currently under development. We described that effector T cells can be converted in regulatory T cells by LV-mediated FOXP3-gene transfer in differentiated T lymphocytes. Despite FOXP3 mutations mainly affect a highly specific T cell subset, manipulation of stem cells could be required for long-term remission of the disease. Therefore, we believe that a more comprehensive strategy should aim at correcting FOXP3-mutated stem cells. Potentials and hurdles of both strategies will be highlighted here. Bentham Science Publishers 2014-12 2014-12 /pmc/articles/PMC4443799/ /pubmed/25274247 http://dx.doi.org/10.2174/1566523214666141001123828 Text en © 2014 Bentham Science Publishers http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Passerini, Laura Santoni de Sio, Francesca R. Porteus, Matthew H. Bacchetta, Rosa Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome |
title | Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome |
title_full | Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome |
title_fullStr | Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome |
title_full_unstemmed | Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome |
title_short | Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome |
title_sort | gene/cell therapy approaches for immune dysregulation polyendocrinopathy enteropathy x-linked syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443799/ https://www.ncbi.nlm.nih.gov/pubmed/25274247 http://dx.doi.org/10.2174/1566523214666141001123828 |
work_keys_str_mv | AT passerinilaura genecelltherapyapproachesforimmunedysregulationpolyendocrinopathyenteropathyxlinkedsyndrome AT santonidesiofrancescar genecelltherapyapproachesforimmunedysregulationpolyendocrinopathyenteropathyxlinkedsyndrome AT porteusmatthewh genecelltherapyapproachesforimmunedysregulationpolyendocrinopathyenteropathyxlinkedsyndrome AT bacchettarosa genecelltherapyapproachesforimmunedysregulationpolyendocrinopathyenteropathyxlinkedsyndrome |